News Release Details

Opiant Pharmaceuticals to Ring The Nasdaq Opening Bell on December 20, 2017

December 19, 2017 at 8:00 AM EST

SANTA MONICA, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it will ring the Nasdaq Opening Bell on Wednesday, December 20, 2017.

“We are honored to be ringing the Nasdaq Opening Bell to celebrate our uplisting to the Nasdaq Stock Market,” said Roger Crystal, M.D., Chief Executive Officer of Opiant.  “We are working every day to develop novel therapeutics for the benefit of patients with addictions.  Being listed on Nasdaq has increased our visibility with investors and helped position us well to create long-term stockholder value.”

Opiant’s common stock was approved for listing on the Nasdaq Capital Market on August 29, 2017.

A live webcast of the honorary opening bell ceremony, courtesy of Nasdaq, will begin at 9:15 am ET on Wednesday, December 20, 2017, and will be available at

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. NIDA, a division of the NIH, describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Its first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by the company’s partner, Adapt Pharma Operations Limited. For more information please visit:

Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Dan Ferry
Managing Director
LifeSci Advisors, LLC
(617) 535-7746

Primary Logo

Source: Opiant Pharmaceuticals, Inc.